Phage Biotechnology Corp. : Company Profile

Company Profile

labpic Phage Biotechnology Corporation (Phage) is a Delaware Corporation, incorporated in 1998 and headquartered in Las Vegas, Nevada. The company has its manufacturing plant in San Diego, California, and will acquire additional space for quality control soon - adjacent to the manufacturing facility. In addition, the company has a pre-clinical research center in Kiev, Ukraine. Currently Phage has approximately 55 employees worldwide. The Company was formed to manufacture recombinant protein pharmaceuticals as either “bio-similar” drugs, or as new drug entities. The company has a portfolio of proprietary pegylated protein products that are rapidly advancing through pre-clinical development.

Phage manufactures protein pharmaceuticals that fall into three main classes, including 1) “bio-similar” versions of marketed drugs whose patents have expired, 2) new drug candidates developed by Phage that will undergo clinical trials, including longer-acting pegylated versions of marketed protein products, and 3) a new class of biopharmaceuticals, Single Chain Antibodies, that will compete with monoclonal antibodies for the treatment of cancer, arthritis, and autoimmune diseases. Utilizing a proprietary process, recombinant proteins can be produced relatively rapidly and at low cost utilizing the Phage manufacturing process. This technology is being applied to the production of key protein pharmaceuticals, with multi-billion dollar estimated market values.

As a result of this production advantage, Phage is targeting the production and sale of drugs that no longer have patent protection. It is anticipated that the primary method for developing sales will be to offer buyers of these types of drugs a substantial price discount compared to all other pharmaceutical producers. It is estimated that Phage can discount its sales price for these drugs from between 30% to 50% of the sales price other companies are charging for the identical drugs. Even marketing these drugs at discounted levels will provide Phage with significant profit margins, in large part as a result of the minimal costs associated with manufacturing these drugs utilizing the Phage system. In addition to developing biopharmaceuticals whose patents have expired, Phage is also developing new pegylated versions of these drugs that should substantially increase the marketplace for these drugs. Most protein drugs must be injected, some daily, but pegylated versions of these drugs often go to once-weekly injections due to their much expanded half-life in the body’s circulation.

Top